Biogen Just Spent $5.6 Billion on a Comeback Story

The $1.5 Billion Bet Behind the Bonus Check

The deal's CVR structure tells you exactly where Biogen thinks the upside lives. Those bonus payments ($2 per share each, up to $4 total) kick in only if SYFOVRE hits $1.5 billion and then $2 billion in annual global net sales between 2027 and 2031.

That means Biogen needs to roughly triple SYFOVRE's current revenue within five years. There's even a catch-up provision: if SYFOVRE doesn't hit $1.5 billion in any earlier year but clears $2 billion by 2031, shareholders get the full $4 in one shot.

It's an ambitious target. SYFOVRE's injection volume grew 17% in 2025, but actual revenue dipped slightly (from $612 million in 2024 to $587 million) because Apellis was handing out free product to build market share. Biogen is betting that once the giveaways taper off and a prefilled syringe (submission planned for the first half of 2026) makes injections easier, revenue will follow the demand curve upward.

Why Biogen Didn't Buy This for the Eye Drops

The ophthalmology asset is nice. But read between the lines, and this deal is really about kidneys.

Biogen already owns felzartamab, a late-stage immunology drug it picked up through its 2024 acquisition of HI-Bio. Felzartamab is being developed for IgA nephropathy, primary membranous nephropathy, and kidney transplant complications. The problem? Biogen didn't have a nephrology salesforce to launch it.

Apellis solves that problem overnight. EMPAVELI's recent expansion into C3 glomerulopathy means Apellis already has reps calling on nephrologists, payer relationships locked in (about 95% of published policies cover EMPAVELI), and clinical credibility in the space. Biogen gets a ready-made commercial engine for its own kidney drugs, plus EMPAVELI's pipeline, which includes pivotal trials in FSGS (focal segmental glomerulosclerosis) and delayed graft function, both areas with zero approved therapies.

Think of it like buying a restaurant not just for the menu, but for the kitchen, the staff, and the regulars who already come in every week.

Wall Street's Verdict: Intrigued, Not Convinced

Analysts mostly agree the strategic logic makes sense. The execution? That's where they get cautious.

The 140% premium to Apellis's earlier trading levels raised eyebrows. Remember, Apellis hit an all-time high of $93.31 in June 2023 before cratering in 2025. Biogen's $41 offer sits awkwardly in the middle: well above the lows, well below the highs.

Stifel analyst Paul Matteis calculated that at consensus estimates of around $1.5 billion in Apellis revenue by 2030, the upfront price implies about a 3.5x revenue multiple. His assessment: "not crazy at all," but ambitious given what EMPAVELI and SYFOVRE would need to deliver.

Barclays kept its Equalweight rating on Biogen with a $185 price target, noting the deal fits within the $5-6 billion framework management had previously outlined. Piper Sandler was more bullish, upgrading Biogen to Overweight with a $214 target. J.P. Morgan, meanwhile, downgraded Apellis to Neutral and simply marked the stock to the $41 deal price.

The most telling signal? Biogen's stock fell on the announcement day despite a rising market. Investors want proof before they celebrate.

William Blair captured the mood perfectly, describing the post-deal sentiment as a "show-me story." EMPAVELI needs to prove it can become a major growth engine (some analysts peg the bar at $600 million or more in annual sales). SYFOVRE needs to re-accelerate. And the felzartamab synergy needs to materialize in actual prescriptions, not just PowerPoint slides.

The Bigger Picture

Biogen plans to fund the deal with cash and borrowings, aiming to fully pay down the debt by the end of 2027. The financial risk is manageable.

But the strategic risk is real. Biogen is no longer just a neurology company that dabbles in other things. With Reata (acquired previously for rare disease), HI-Bio (kidney immunology), and now Apellis (complement and ophthalmology), the company is assembling a diversified portfolio that looks almost nothing like it did three years ago.

That's either visionary portfolio-building or identity crisis spending. The difference will come down to one thing: whether SYFOVRE and EMPAVELI grow into the revenue targets baked into that $5.6 billion price tag.

Biogen has placed its bet. Now it has to hit its numbers.